{"id":33671,"date":"2020-08-27T11:14:13","date_gmt":"2020-08-27T10:14:13","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33671"},"modified":"2023-05-03T22:18:09","modified_gmt":"2023-05-03T21:18:09","slug":"nicolas-buchmann","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/","title":{"rendered":"Nicolas Buchmann"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Dr. Nicolas Buchmann<\/h2>\n<h4>Programme Manager at Vectura Group plc.<\/h4>\n\t<p>Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager and is leading drug-device combination programmes with pMDIs, development projects with connected inhalation devices, smart nebuliser technology developments and was also deeply involved in the development of novel aerosol generation technologies. At his work at Vectura. His educational background is engineering profession with a Doctor of Philosophy in Mechanical and Biomedical Engineering<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1.jpg\" alt=\"Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tSmart Nebulisers &#8211; Opportunities for Development of Drug Products\n\t<\/h3>\n<div class=\"su-expand su-expand-collapsed su-expand-link-style-default\" data-height=\"200\"><div class=\"su-expand-content su-u-trim\" style=\"color:#333333;max-height:200px;overflow:hidden\">\n<ul>\n<li>A number of companies (ranging from large to speciality pharma) have strategic initiatives to reposition or repurpose known chemical entities &#8220;old drugs&#8221; for or within inhalation therapy. Many of these programmes are focussed on developing value-added or differentiated products for &#8220;on target&#8221; respiratory or &#8220;off-target&#8221; systemic indications to meet a particular unmet therapeutic need. With lower risk profile compared to New Chemical Entity (NCE) product developments using known drugs offer new opportunities by using new technologies<\/li>\n<li>Products delivered via smart nebulisation, e.g., via AKITA\u00ae JET or FOX\u00ae nebulisers, can provide the value propositions that merit their development as repositioned drugs. These nebulisers guide patients achieve the correct inhalation technique and deliver a greater proportion of drug to the lungs with reduced variability, as well as monitor treatment compliance through their connectivity. These attributes may improve patient outcomes and lead to better patient satisfaction and adherence. In both products, a Bluetooth-enabled app records inhalation and adherence data for sharing with the caregiver or physician<\/li>\n<li>Many poorly treated orphan, rare, or neglected respiratory diseases are benefiting from such repositioned developments providing efficacious licensed products to patients where previously few existed or where off-label drug use is common. Repositioned product developments include anti-infectives for a variety of conditions; CF, NCFB, MAC and tuberculosis, as well as, products to treat niche indications; in lung cancer, severe uncontrolled asthma\/COPD, chronic cough, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH) etc<\/li>\n<\/ul>\n<\/div><div class=\"su-expand-link su-expand-link-more\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show more<\/span><\/a><\/div><div class=\"su-expand-link su-expand-link-less\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show less<\/span><\/a><\/div><\/div>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.vectura.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.vectura.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/nicolas-buchmann-5a658045\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Dr. Nicolas Buchmann Programme Manager at Vectura Group plc. Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager and is leading drug-device combination programmes with pMDIs, development projects with connected inhalation devices, smart nebuliser technology developments and was also deeply involved in the development&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33672,"parent":33607,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33671","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nicolas Buchmann &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicolas Buchmann &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-03T21:18:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/\",\"name\":\"Nicolas Buchmann &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg\",\"datePublished\":\"2020-08-27T10:14:13+00:00\",\"dateModified\":\"2023-05-03T21:18:09+00:00\",\"description\":\"Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhalation &#038; Respiratory Drug Delivery 2019 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nicolas Buchmann\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicolas Buchmann &#8226; BioTech Pharma Summit","description":"Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/","og_locale":"en_US","og_type":"article","og_title":"Nicolas Buchmann &#8226; BioTech Pharma Summit","og_description":"Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-05-03T21:18:09+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/","name":"Nicolas Buchmann &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg","datePublished":"2020-08-27T10:14:13+00:00","dateModified":"2023-05-03T21:18:09+00:00","description":"Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Inhalation &#038; Respiratory Drug Delivery 2019 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/"},{"@type":"ListItem","position":3,"name":"Nicolas Buchmann"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33671"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33671\/revisions"}],"predecessor-version":[{"id":38320,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33671\/revisions\/38320"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33672"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}